Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Somewhat Bearish -42

Moderna in the spotlight: Can pipeline offset earnings decline? - Investing.com

📉 Moderna is set to report Q1 earnings Friday morning after a 63% sequential revenue decline from $678M in Q4.

💸 Analysts forecast a Q1 loss of $2.02 per share on projected revenue of $251.76 million.

📊 Wall Street caution is evident as EPS estimates dropped 36% and revenue estimates fell roughly 5% over the past week.

🏦 The stock trades at $45.72, trading near analyst consensus targets with a majority of ratings holding or recommending sell.

💉 Investors are focused on mRESVIA RSV vaccine momentum, which currently holds 34% market share in the 65+ demographic.

💊 The European Commission's approval of mCOMBRIAX for influenza and COVID-19 represents a key growth driver for the diversified pipeline.

🔬 Melanoma cancer vaccine data showing a 49% reduction in death rates is closely watched as potential Phase 3 catalysts emerge.

🐦 Moderna continues its bird flu vaccine trial with 4,000 participants despite significant loss of federal funding and political headwinds.

🚀 The company aims for up to 10% revenue growth in 2026 and cash breakeven by 2028 following Q1 2025 reporting.

📈 Management faces the challenge of articulating a credible path from $251M quarterly revenue to sustainable profitability.

Bullish Signals
  • Moderna's mRESVIA RSV vaccine has captured roughly 34% market share in the 65-and-older segment.
  • The European Commission approved mCOMBRIAX on April 21, marking it as the world's first mRNA combination vaccine for influenza and COVID-19.
  • Moderna's melanoma cancer vaccine developed with Merck showed a 49% reduction in death rates over five years in data released in January.
  • Moderna continues to push ahead with its bird flu vaccine trial, enrolling roughly 4,000 participants in a late-stage study.
  • Barclays raised its price target for Moderna to $48 from $25 earlier this month.
  • The company aims to achieve up to 10% revenue growth in 2026 and reach cash breakeven by 2028.
Risk Factors
  • Moderna is facing a sharp sequential revenue drop of approximately 63% as it pivots from its pandemic-era business model to a diversified vaccine franchise.
  • Analysts expect a loss of $2.02 per share on revenue of $251.76 million for the first quarter, indicating continued profitability challenges.
  • Wall Street has grown more cautious with EPS estimates falling 36% over the past week while revenue estimates have declined roughly 5% in the same period.
  • The stock trades at $45.72, implying a downside risk against analyst consensus price targets of $41.42 which suggest roughly 9% downside from current levels.
  • Of the 23 analysts covering the stock, only three rate it a buy while three recommend selling, reflecting significant investor skepticism.
  • Investors are concerned about whether declining COVID vaccine sales can be offset by mRESVIA RSV vaccine which has captured roughly 34% market share in the 65-and-older segment but lacks broader momentum.
  • Moderna is pushing ahead with its bird flu vaccine trial despite losing hundreds of millions in federal funding and facing political headwinds around mRNA technology.
  • The company faces a significant challenge transitioning from a $251 million quarterly revenue run rate to sustainable profitability to achieve its stated goal of reaching cash breakeven by 2028.
Full Analysis
Moderna Inc. is preparing to report its first-quarter earnings ahead of a Friday market open, with investors anticipating a significant revenue decline as the company transitions away from its pandemic-era dominance. Analysts project a loss of $2.02 per share on expected revenue of $251.76 million, marking a 63% drop from the $678 million reported in the fourth quarter and reflecting a slight improvement from last quarter's $2.11 per share loss. Despite this anticipated downturn, Wall Street sentiment has softened, with EPS estimates falling 36% over the past week while revenue estimates have slipped roughly 5%, contributing to a stock price of $45.72 that remains below its 52-week high of $59.55. Analyst consensus holds a neutral stance, rating Moderna as a hold with a median price target of $41.42, suggesting approximately 9% downside from current levels, though Barclays recently revised its target upward to $48 from $25. Investors are closely evaluating whether Moderna's diverse vaccine pipeline can offset the anticipated slump in COVID vaccine sales, which will be tested through upcoming revenue guidance. The company has secured strong market penetration with its mRESVIA RSV vaccine, capturing about 34% market share in the 65-and-older demographic, while also gaining regulatory momentum with the European Commission's approval on April 21 of mCOMBRIAX, the first mRNA combination vaccine for influenza and COVID-19. Furthermore, updates on the collaboration with Merck regarding its melanoma cancer vaccine are critical; January data showed a 49% reduction in death rates over five years, keeping Phase 3 readouts as potential catalysts for growth and validating the company's strategic pivot toward non-COVID franchises. Beyond product approvals, Moderna faces significant financial headwinds and operational challenges that could impact its path to profitability. The firm is proceeding with high-risk bird flu vaccine trials, enrolling roughly 4,000 participants in a late-stage study despite losing hundreds of millions in federal funding amid political scrutiny of mRNA technology. This quarter marks the last period before Moderna aims to execute its long-term goals of achieving up to 10% revenue growth by 2026 and reaching cash breakeven by 2028. The market will scrutinize management's ability to articulate a credible strategy for scaling from the current $251 million quarterly run rate to sustainable profitability, as this transition determines if the stock can break out of its recent trading range between $22.28 and $59.55.